Key references: Apixaban and rivaroxaban poisonings

Bekka E, Liakoni E. Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-alpha, protamine). Br J Clin Pharmacol 2024. https://www.ncbi.nlm.nih.gov/pubmed/38926082
Clinical Excellence Commission. Non-vitamin K antagonist oral anticoagulants (NAOC) guidelines, updated July 2017. Sydney: Clinical Excellence Commission; 2017. http://www.cec.health.nsw.gov.au/patient-safety-programs/medication-safety/high-risk-medicines/anticoagulants
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor xa inhibitors. N Engl J Med 2019;380(14):1326–35. https://www.ncbi.nlm.nih.gov/pubmed/30730782
Heo YA. Andexanet alfa: First global approval. Drugs 2018;78(10):1049–55. https://www.ncbi.nlm.nih.gov/pubmed/29926311
Levine M, Beuhler MC, Pizon A, Cantrel FL, Spyres MB, LoVecchio F, et al. Assessing bleeding risk in patients with intentional overdoses of novel antiplatelet and anticoagulant medications. Ann Emerg Med 2018;71(3):273–8. https://www.ncbi.nlm.nih.gov/pubmed/29032872
Ollier E, Hodin S, Lanoiselee J, Escal J, Accassat S, De Magalhaes E, et al. Effect of activated charcoal on rivaroxaban complex absorption. Clin Pharmacokinet 2017;56(7):793–801. https://www.ncbi.nlm.nih.gov/pubmed/27910037
Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, et al. An observational study of the Factor Xa inhibitors rivaroxaban and apixaban as reported to eight poison centers. Ann Emerg Med 2016;67(2):189–95. https://www.ncbi.nlm.nih.gov/pubmed/26298448
Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 2014;44(6):525–36. https://www.ncbi.nlm.nih.gov/pubmed/24946813
Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014;14(2):147–54. https://www.ncbi.nlm.nih.gov/pubmed/24277644